Publications by authors named "Mark Stroh"

Claim this Profile
C
Clinical Pharmacology and Translational Considerations in the Development of CRISPR-Based Therapies.
Ahmed M Abdelhady, Jonathan A Phillips, Yuanxin Xu, Mark Stroh

Clin Pharmacol Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.
Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Mark Stroh

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Rachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, Patrick A Ott, Javier Garcia-Corbacho, Mark Stroh

J Immunother Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Aung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, Ferry A L M Eskens, Nataliya Uboha, Mark Stroh

J Immunother Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072.
Mark Stroh, Michelle Green, Bjorn L Millard, Joshua F Apgar, John M Burke

Clin Pharmacol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody.
Mark Stroh, Jason Sagert, John M Burke, Joshua F Apgar, Lin Lin

CPT Pharmacometrics Syst Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients.
Ida Netterberg, Chi-Chung Li, Luciana Molinero, Nageshwar Budha, Siddharth Sukumaran, Mark Stroh

Clin Pharmacol Ther· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Laurent Claret, Jin Y Jin, Charles Ferté, Helen Winter, Sandhya Girish, Mark Stroh

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing In and Around Tolerability Considerations for Immunotherapy Combinations.
Mark Stroh

Clin Pharmacol Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Mark Stroh

Oncologist· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Mark Stroh

Oncologist· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.
Kelong Han, Pascal Chanu, Fredrik Jonsson, Helen Winter, René Bruno, Mark Stroh

AAPS J· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.
Mark Stroh, Michelle Green, Edward Cha, Nancy Zhang, Russ Wada

Cancer Chemother Pharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
Dan Lu, Tong Lu, Mark Stroh, Richard A Graham, Priya Agarwal

Cancer Chemother Pharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Marie T Borin, Meng Chen, Simonetta Mocci, Igor Rubets, Jason Chittenden, Mark Stroh

Cancer Chemother Pharmacol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation.
Mark Stroh, Jennifer Talaty, Punam Sandhu, Jacqueline McCrea, Amita Patnaik

J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans.
Christopher R Gibson, Ping Lu, Cheri Maciolek, Christen Wudarski, Zoe Barter, Mark Stroh

Xenobiotica· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites.
Mark Stroh, Matthew M Hutmacher, Jianmei Pang, Ryan Lutz, Hiroshi Magara

AAPS J· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
Richard M Lush, Amita Patnaik, Daniel Sullivan, Kyriakos P Papadopoulos, Michele Trucksis, Mark Stroh

Cancer Chemother Pharmacol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The minimal impact of food on the pharmacokinetics of ridaforolimus.
Mark Stroh, Xiaodong Li, Sabrina Marsilio, Deborah Panebianco, Amy Johnson-Levonas

Cancer Chemother Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Mark Stroh, John Palcza, Jacqueline McCrea, Sabrina Marsilio, Sheila Breidinger

Cancer Chemother Pharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice.
Jie Wei, Jeffrey Jones, Jing Kang, Ananda Card, Michael Krimm, Mark Stroh

Mol Pharmacol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
Waldemar Radziszewski, Eseng Lai, Nicole Lazarus Shipitofsky, Mark Stroh, Victor Dishy

Am J Ther· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.
Mark Stroh, Victor Dishy, Waldemar Radziszewski, Eunhee Hwang, Nicole Lazarus-Shipitofsky

Am J Ther· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
Jules I Schwartz, Mark Stroh, Bing Gao, Fang Liu, Kimberly Rosko

Cardiovasc Ther· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis